{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:12:26Z","timestamp":1793747546849,"version":"4.6.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    Vascular malformations of the head and neck carry high morbidity because of their proximity to the airway, cranial nerves, sensory organs, and cerebral vasculature. Although the ISSVA classification of vascular anomalies has standardized diagnostic terminology, therapeutic decisions for malformations have remained largely phenotype-driven and procedure-centered. Recent advances in genomics reveal that many vascular malformations are genetically driven disorders of endothelial signaling, enabling a transition toward etiological, mechanism-based therapy. This review presents a molecularly guided precision framework for the management of head and neck vascular malformations, focusing specifically on etiological medications that modify underlying disease biology. We synthesize evidence supporting three principal therapeutic classes: mTOR inhibition for PI3K-AKT\u2013mTOR-driven disease, direct PI3K\u03b1 inhibition for\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -mediated pathology, and MEK inhibition for RAS\/MAPK-driven lesions. We summarize translational and clinical evidence and provide practical guidance on indications, expected responses, toxicity monitoring, and sequencing for head and neck lesions. By reframing treatment selection around molecular drivers rather than descriptive phenotype, this review introduces a clinically actionable paradigm that advances care for vascular malformations from lesion control toward durable, mechanism-based disease modification.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2026.1796746","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:39:11Z","timestamp":1773812351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Vascular malformations of the head and neck and a molecularly guided precision therapy framework"],"prefix":"10.3389","volume":"17","author":[{"given":"Hui-Qi","family":"Qu","sequence":"first","affiliation":[{"name":"The Center for Applied Genomics, Children\u2019s Hospital of Philadelphia","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[{"name":"The Center for Applied Genomics, Children\u2019s Hospital of Philadelphia","place":["Philadelphia, PA, United States"]},{"name":"Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Division of Human Genetics, Children\u2019s Hospital of Philadelphia","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakon","family":"Hakonarson","sequence":"additional","affiliation":[{"name":"The Center for Applied Genomics, Children\u2019s Hospital of Philadelphia","place":["Philadelphia, PA, United States"]},{"name":"Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Division of Human Genetics, Children\u2019s Hospital of Philadelphia","place":["Philadelphia, PA, United States"]},{"name":"Division of Pulmonary Medicine, Children\u2019s Hospital of Philadelphia","place":["Philadelphia, PA, United States"]},{"name":"Faculty of Medicine, University of Iceland","place":["Reykjavik, Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1542\/peds.2014-3673","article-title":"Vascular anomalies classification: recommendations from the International Society for the Study of vascular anomalies","volume":"136","author":"Wassef","year":"2015","journal-title":"Pediatrics"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/jova.0000000000000113","article-title":"Updated classification of vascular anomalies: a living document from the International Society for the Study of vascular anomalies classification group","volume":"6","author":"Goldenberg","year":"2025","journal-title":"J Vasc Anomalies"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"150968","DOI":"10.1016\/j.sempedsurg.2020.150968","article-title":"Vascular anomalies of the head and neck","volume":"29","author":"Alsuwailem","year":"2020","journal-title":"Semin Pediatr Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-023-02364-x","article-title":"Genomic profiling informs diagnoses and treatment in vascular anomalies","volume":"29","author":"Li","year":"2023","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"eabg0809","DOI":"10.1126\/scitranslmed.abg0809","article-title":"Alpelisib administration reduced lymphatic malformations in a mouse model and in patients","volume":"13","author":"Delestre","year":"2021","journal-title":"Sci Transl Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/circresaha.121.318145","article-title":"Genetic basis and therapies for vascular anomalies","volume":"129","author":"Queisser","year":"2021","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"332ra42","DOI":"10.1126\/scitranslmed.aaf1164","article-title":"Somatic PIK3CA mutations as a driver of sporadic venous malformations","volume":"8","author":"Castel","year":"2016","journal-title":"Sci Transl Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00109-015-1352-5","article-title":"Molecules in medicine mini-review: isoforms of PI3K in biology and disease","volume":"94","author":"Vanhaesebroeck","year":"2016","journal-title":"J Mol Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220741","article-title":"Immune-interacting lymphatic endothelial subtype at capillary terminals drives lymphatic malformation","volume":"220","author":"Petkova","year":"2023","journal-title":"J Exp Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/ng.272","article-title":"Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations","volume":"41","author":"Limaye","year":"2009","journal-title":"Nat Genet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ajhg.2015.11.011","article-title":"Somatic activating PIK3CA mutations cause venous malformation","volume":"97","author":"Limaye","year":"2015","journal-title":"Am J Hum Genet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"25440","DOI":"10.1038\/s41598-024-72167-8","article-title":"Defining the transcriptome of PIK3CA-altered cells in a human capillary malformation using single cell long-read sequencing","volume":"14","author":"Wedemeyer","year":"2024","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jamadermatol.2021.3459","article-title":"Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial","volume":"157","author":"Maruani","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/cts.13488","article-title":"Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations - a nationwide trial","volume":"16","author":"Harbers","year":"2023","journal-title":"Clin Transl Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s12325-021-01758-y","article-title":"Patients with congenital Low-flow vascular malformation treated with Low dose Sirolimus","volume":"38","author":"Harbers","year":"2021","journal-title":"Adv Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"ref22","volume-title":"Highlights of Prescribing Information: PIQRAY\u00ae (Alpelisib) Tablets, for Oral Use","year":"2024"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"Map kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrm3979","article-title":"Regulation of RAF protein kinases in ERK signalling","volume":"16","author":"Lavoie","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1056\/NEJMoa1709449","article-title":"Somatic activating KRAS mutations in arteriovenous malformations of the brain","volume":"378","author":"Nikolaev","year":"2018","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149831","article-title":"KRAS-driven model of Gorham-stout disease effectively treated with trametinib","volume":"6","author":"Homayun-Sepehr","year":"2021","journal-title":"JCI Insight"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1172\/JCI98589","article-title":"Mosaic RAS\/MAPK variants cause sporadic vascular malformations which respond to targeted therapy","volume":"128","author":"Al-Olabi","year":"2018","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ajhg.2017.01.018","article-title":"Somatic MAP2K1 mutations are associated with Extracranial arteriovenous malformation","volume":"100","author":"Couto","year":"2017","journal-title":"Am J Hum Genet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41390-022-01986-0","article-title":"Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition","volume":"94","author":"Chowers","year":"2023","journal-title":"Pediatr Res"},{"key":"ref31","volume-title":"MEKINIST\u00ae (Trametinib) Tablets: Prescribing Information","year":"2022"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory Chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J Pediatr"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1182\/hematology.2024000599","article-title":"Targeted medical therapies for vascular anomalies","volume":"2024","author":"Borst","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41436-020-00943-8","article-title":"Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations","volume":"23","author":"Zenner","year":"2021","journal-title":"Genet Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/1539685041690436","article-title":"Lymphatic malformations","volume":"2","author":"Smith","year":"2004","journal-title":"Lymphat Res Biol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4103\/ds.DS-D-23-00060","article-title":"Successful treatment with everolimus for microcystic lymphangioma of the tongue caused by a somatic PIK3CA mutation","volume":"42","author":"Chang","year":"2024","journal-title":"Dermatol Sin"},{"key":"ref38","volume-title":"An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations","year":"2022"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101255","article-title":"Therapeutic drug monitoring for sirolimus in children with vascular anomalies: what can we learn from a retrospective study","volume":"17","author":"Hu","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","article-title":"FDA approval summary: Alpelisib for PIK3CA-related overgrowth Spectrum","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.gim.2022.07.026","article-title":"Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth","volume":"24","author":"Wenger","year":"2022","journal-title":"Genet Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/jova.0000000000000038","article-title":"Clinical response to PI3K-\u03b1 inhibition in a cohort of children and adults with PIK3CA-related overgrowth spectrum disorders","volume":"3","author":"Raghavendran","year":"2022","journal-title":"J Vasc Anom (Phila)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74510","article-title":"Genomic landscape of lymphatic malformations: a case series and response to the PI3K\u03b1 inhibitor alpelisib in an N-of-1 clinical trial","volume":"11","author":"Shaheen","year":"2022","journal-title":"eLife"},{"key":"ref44","volume-title":"Alpelisib (Piqray): CADTH Reimbursement Review: Clinical Review, CADTH Reimbursement Review","year":"2022"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e28036","DOI":"10.1002\/pbc.28036","article-title":"Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus","volume":"67","author":"Iacobas","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/jop.13353","article-title":"Current classification of vascular anomalies of the head and neck","volume":"51","author":"Oomen","year":"2022","journal-title":"J Oral Pathol Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3978\/j.issn.2223-4292.2015.04.06","article-title":"Vascular anomalies of the head and neck in children","volume":"5","author":"Mahady","year":"2015","journal-title":"Quant Imaging Med Surg"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.7181\/acfs.2018.02383","article-title":"Vascular anomalies of the head and neck: current overview","volume":"19","author":"Lee","year":"2018","journal-title":"Arch Craniofac Surg"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoto.2020.4353","article-title":"Contemporary management of vascular anomalies of the head and neck-part 1: vascular malformations: a review","volume":"147","author":"Gallant","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3174\/ajnr.A3180","article-title":"Head and neck arteriovenous malformations: results of ethanol sclerotherapy","volume":"34","author":"Pekkola","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"101597","DOI":"10.1016\/j.jvscit.2024.101597","article-title":"Embolization and sclerotherapy for head and neck arteriovenous malformations with uncontrollable torrential bleeding","volume":"10","author":"Zhang","year":"2024","journal-title":"J Vasc Surg Cases Innov Tech"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173095","article-title":"Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations","volume":"8","author":"Seront","year":"2023","journal-title":"JCI Insight"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ijwd.2021.10.014","article-title":"Targeted treatment of vascular anomalies","volume":"7","author":"Ng","year":"2021","journal-title":"Int J Women's Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejro.2017.05.001","article-title":"Interdisciplinary Management of Head and Neck Vascular Anomalies: clinical presentation, diagnostic findings and Minimalinvasive therapies","volume":"4","author":"Sadick","year":"2017","journal-title":"Eur J Radiol Open"},{"key":"ref55","year":"2019"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1796746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:39:14Z","timestamp":1773812354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1796746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":55,"alternative-id":["10.3389\/fneur.2026.1796746"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1796746","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1796746"}}